A few of these (regions associated with ADAMTS1, SCARF2, and DSCR9) were tested further, and in combination, showed ~100% sensitivity and ~85% specificity for prostate cancer compared to matched adjacent benign tissues. This evidence concerns the gene DSCR9 and prostate cancer.